CN101479389A - 丙肝病毒感染生物标记 - Google Patents

丙肝病毒感染生物标记 Download PDF

Info

Publication number
CN101479389A
CN101479389A CNA200780023526XA CN200780023526A CN101479389A CN 101479389 A CN101479389 A CN 101479389A CN A200780023526X A CNA200780023526X A CN A200780023526XA CN 200780023526 A CN200780023526 A CN 200780023526A CN 101479389 A CN101479389 A CN 101479389A
Authority
CN
China
Prior art keywords
activity
subject
gene
binding
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780023526XA
Other languages
English (en)
Chinese (zh)
Inventor
R·K·拉玛查恩德兰
M·W·哈丁
P·R·卡隆
M·C·伯特菲尔德
B·J·哈尔
R·班达鲁
K·M·克利赫尔
C·N·考纳尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101479389A publication Critical patent/CN101479389A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200780023526XA 2006-04-26 2007-04-25 丙肝病毒感染生物标记 Pending CN101479389A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
US60/795,520 2006-04-26

Publications (1)

Publication Number Publication Date
CN101479389A true CN101479389A (zh) 2009-07-08

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780023526XA Pending CN101479389A (zh) 2006-04-26 2007-04-25 丙肝病毒感染生物标记

Country Status (13)

Country Link
US (1) US20100028874A1 (https=)
EP (1) EP2016195A4 (https=)
JP (1) JP2009535036A (https=)
KR (1) KR20090023360A (https=)
CN (1) CN101479389A (https=)
AU (1) AU2007244824A1 (https=)
CA (1) CA2650616A1 (https=)
IL (1) IL194920A0 (https=)
MX (1) MX2008013796A (https=)
NO (1) NO20084954L (https=)
NZ (1) NZ573052A (https=)
RU (1) RU2008146518A (https=)
WO (1) WO2007127801A2 (https=)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
CN103119444A (zh) * 2010-04-21 2013-05-22 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
CN106456677A (zh) * 2014-04-11 2017-02-22 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
US9726668B2 (en) 2012-02-09 2017-08-08 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN108379584A (zh) * 2018-04-12 2018-08-10 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US10303846B2 (en) 2014-08-14 2019-05-28 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
CN110448548A (zh) * 2018-05-08 2019-11-15 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
CN111333710A (zh) * 2020-03-04 2020-06-26 暨南大学 C20orf24蛋白缺失突变体及其应用
US10859574B2 (en) 2014-10-14 2020-12-08 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
US11131671B2 (en) 2016-07-10 2021-09-28 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
US12338497B2 (en) 2016-03-03 2025-06-24 Memed Diagnostics Ltd. Analyzing RNA for diagnosing infection type
US12392775B2 (en) 2014-12-11 2025-08-19 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
EA201170484A1 (ru) * 2008-09-24 2012-03-30 Вертекс Фармасьютикалз Инкорпорейтед Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
AU2017278254A1 (en) * 2016-06-07 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
KR102289533B1 (ko) * 2019-08-19 2021-08-17 주식회사 테라젠바이오 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
WO2006072075A2 (en) * 2004-12-30 2006-07-06 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9791446B2 (en) 2010-04-21 2017-10-17 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN103119444A (zh) * 2010-04-21 2013-05-22 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
CN103119444B (zh) * 2010-04-21 2016-10-26 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
CN106442984A (zh) * 2010-04-21 2017-02-22 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
CN106442984B (zh) * 2010-04-21 2020-03-13 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
US12188934B2 (en) 2012-02-09 2025-01-07 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US11175291B2 (en) 2012-02-09 2021-11-16 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US10502739B2 (en) 2012-02-09 2019-12-10 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US9726668B2 (en) 2012-02-09 2017-08-08 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN106456677A (zh) * 2014-04-11 2017-02-22 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
US11304996B2 (en) 2014-04-11 2022-04-19 The Regents Of The University Of Colorado, A Body Corporate Yeast-based immunotherapy and type I interferon sensitivity
US12131807B2 (en) 2014-08-14 2024-10-29 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US10303846B2 (en) 2014-08-14 2019-05-28 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US11776658B2 (en) 2014-08-14 2023-10-03 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US11450406B2 (en) 2014-08-14 2022-09-20 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US11081206B2 (en) 2014-08-14 2021-08-03 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
CN107427552A (zh) * 2014-08-22 2017-12-01 中国科学院生物物理研究所 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
US10859574B2 (en) 2014-10-14 2020-12-08 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
US12392775B2 (en) 2014-12-11 2025-08-19 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
US12338497B2 (en) 2016-03-03 2025-06-24 Memed Diagnostics Ltd. Analyzing RNA for diagnosing infection type
US11466331B2 (en) 2016-03-03 2022-10-11 Memed Diagnostics Ltd. RNA determinants for distinguishing between bacterial and viral infections
US12044681B2 (en) 2016-07-10 2024-07-23 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
US11131671B2 (en) 2016-07-10 2021-09-28 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US12055545B2 (en) 2016-07-10 2024-08-06 Memed Diagnostics Ltd. Early diagnosis of infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US12228579B2 (en) 2016-09-29 2025-02-18 Memed Diagnostics Ltd. Methods of prognosis and treatment
US11353456B2 (en) 2016-09-29 2022-06-07 Memed Diagnostics Ltd. Methods of risk assessment and disease classification for appendicitis
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584A (zh) * 2018-04-12 2018-08-10 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548A (zh) * 2018-05-08 2019-11-15 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
CN111333710A (zh) * 2020-03-04 2020-06-26 暨南大学 C20orf24蛋白缺失突变体及其应用

Also Published As

Publication number Publication date
KR20090023360A (ko) 2009-03-04
CA2650616A1 (en) 2007-11-08
WO2007127801A3 (en) 2008-09-12
IL194920A0 (en) 2009-08-03
EP2016195A4 (en) 2010-03-10
JP2009535036A (ja) 2009-10-01
AU2007244824A1 (en) 2007-11-08
NO20084954L (no) 2009-01-22
EP2016195A2 (en) 2009-01-21
WO2007127801A2 (en) 2007-11-08
US20100028874A1 (en) 2010-02-04
NZ573052A (en) 2012-03-30
MX2008013796A (es) 2009-03-31
RU2008146518A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
CN101479389A (zh) 丙肝病毒感染生物标记
Ziegler et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Meissner et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Suppiah et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
US11434522B1 (en) Detection of chromosome interactions
AU2009240021B2 (en) Antiviral therapy
Rosenbaum et al. Hypothesis: sarcoidosis is a STAT1-mediated disease
EP2115169B1 (en) Methods for determining drug sensitivity in patients infected with hcv
Welzel et al. Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial
Manry et al. Deciphering the genetic control of gene expression following Mycobacterium leprae antigen stimulation
JP2007529714A (ja) 遺伝子分析のための方法
US20130059749A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
EP3873523A1 (en) Type i interferon signatures and methods of use
CA3200256A1 (en) Methods and systems of stratifying inflammatory disease patients
Goertsches et al. Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks
HK1130843A (en) Hepatitis c virus infection biomarkers
CN116209758A (zh) 检测磺胺衍生物的抗癫痫药物引起的药物过敏反应的方法及试剂盒，以及试剂盒的用途
US12514832B2 (en) Methods for using low-dose colchicine after myocardial infarction
TW202214873A (zh) 生物標記及其於治療慢性hbv感染之用途
Ansari et al. Interferon lambda 4 impacts broadly on hepatitis C virus diversity
Kowalec The clinical and pharmacogenomic determinants of interferon beta induced liver injury in multiple sclerosis
Omri Characterization of human septic sera induced gene expression modulation in human myocytes
Li Identification and characterization of susceptibility genes and dysregulated signaling pathways in Sjögren's syndrome
JP2018519839A (ja) Ｈｂｖ処置応答に関するバイオマーカー

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130843

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090708

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130843

Country of ref document: HK